{"id":344486,"date":"2026-11-12T10:25:35","date_gmt":"2026-11-12T04:55:35","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=344486"},"modified":"2026-11-12T10:25:35","modified_gmt":"2026-11-12T04:55:35","slug":"automotive-control-cables-maker-business-process-services-company-and-pharma-ingredients-maker-stocks-roadmap-vantage-list","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/automotive-control-cables-maker-business-process-services-company-and-pharma-ingredients-maker-stocks-roadmap-vantage-list\/","title":{"rendered":"3 Automotive Control Cables Maker, Business Process Services Company and Pharma Ingredients Maker Stocks With a Strong Future Roadmap: Suprajit Engineering, Firstsource Solutions and Divi&#8217;s Laboratories"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E84;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Suprajit Engineering, Firstsource Solutions and Divi&#8217;s Laboratories: ROE of 12.7% to 17.1% and FY22 to FY26 revenue CAGR of 5.1% to 20.4%. Prices as of 11 Nov 2026.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E84;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The three control cable, BPO and drug ingredient stocks to watch are Suprajit Engineering, Firstsource Solutions and Divi&#8217;s Laboratories. Their return on equity ranges from 12.7% to 17.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 5.1% to 20.4%. Firstsource Solutions has the highest return on equity at 17.1%, while Suprajit Engineering has the fastest revenue growth at 20.4% a year. Prices are based on the 11 November 2026 close, and this article is educational, not investment advice.<\/p>\n<\/div>\n<p>Control cable, BPO and drug ingredient stocks bring together companies with a visible plan for the years ahead. Suprajit Engineering, Firstsource Solutions and Divi&#8217;s Laboratories cover an automotive control cables maker, a business process services company and a pharma ingredients maker.<\/p>\n<p>This list covers three control cable, BPO and drug ingredient stocks with complete current figures: Suprajit Engineering, Firstsource Solutions and Divi&#8217;s Laboratories. Every figure comes from the latest reported financials and the 11 November 2026 market close. Companies without complete current figures were left out.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=automotive-control-cables-maker-business-process-services-company-and-pharma-ingredients-maker-stocks-roadmap-vantage-list\">Click Here &#8211; Get Free Investment Predictions<\/a><\/strong><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/automotive-control-cables-maker-business-process-services-company-and-pharma-ingredients-maker-stocks-roadmap-vantage-list\/#What_Are_Control_Cable_BPO_and_Drug_Ingredient_Stocks\" title=\"What Are Control Cable, BPO and Drug Ingredient Stocks?\">What Are Control Cable, BPO and Drug Ingredient Stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/automotive-control-cables-maker-business-process-services-company-and-pharma-ingredients-maker-stocks-roadmap-vantage-list\/#Control_Cable_BPO_and_Drug_Ingredient_Stocks_at_a_Glance\" title=\"Control Cable, BPO and Drug Ingredient Stocks at a Glance\">Control Cable, BPO and Drug Ingredient Stocks at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/automotive-control-cables-maker-business-process-services-company-and-pharma-ingredients-maker-stocks-roadmap-vantage-list\/#Why_Do_Control_Cable_BPO_and_Drug_Ingredient_Stocks_Have_a_Strong_Roadmap_in_India\" title=\"Why Do Control Cable, BPO and Drug Ingredient Stocks Have a Strong Roadmap in India?\">Why Do Control Cable, BPO and Drug Ingredient Stocks Have a Strong Roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/automotive-control-cables-maker-business-process-services-company-and-pharma-ingredients-maker-stocks-roadmap-vantage-list\/#Why_Suprajit_Engineering_Features_Among_These_Control_Cable_BPO_and_Drug_Ingredient_Stocks\" title=\"Why Suprajit Engineering Features Among These Control Cable, BPO and Drug Ingredient Stocks\">Why Suprajit Engineering Features Among These Control Cable, BPO and Drug Ingredient Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/automotive-control-cables-maker-business-process-services-company-and-pharma-ingredients-maker-stocks-roadmap-vantage-list\/#Why_Firstsource_Solutions_Features_Among_These_Control_Cable_BPO_and_Drug_Ingredient_Stocks\" title=\"Why Firstsource Solutions Features Among These Control Cable, BPO and Drug Ingredient Stocks\">Why Firstsource Solutions Features Among These Control Cable, BPO and Drug Ingredient Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/automotive-control-cables-maker-business-process-services-company-and-pharma-ingredients-maker-stocks-roadmap-vantage-list\/#Why_Divis_Laboratories_Features_Among_These_Control_Cable_BPO_and_Drug_Ingredient_Stocks\" title=\"Why Divi&#8217;s Laboratories Features Among These Control Cable, BPO and Drug Ingredient Stocks\">Why Divi&#8217;s Laboratories Features Among These Control Cable, BPO and Drug Ingredient Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/automotive-control-cables-maker-business-process-services-company-and-pharma-ingredients-maker-stocks-roadmap-vantage-list\/#Suprajit_Engineering_vs_Firstsource_Solutions_vs_Divis_Laboratories_on_Key_Financials\" title=\"Suprajit Engineering vs Firstsource Solutions vs Divi&#8217;s Laboratories on Key Financials\">Suprajit Engineering vs Firstsource Solutions vs Divi&#8217;s Laboratories on Key Financials<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/automotive-control-cables-maker-business-process-services-company-and-pharma-ingredients-maker-stocks-roadmap-vantage-list\/#Key_Risks_to_Check_Before_Investing_in_Control_Cable_BPO_and_Drug_Ingredient_Stocks\" title=\"Key Risks to Check Before Investing in Control Cable, BPO and Drug Ingredient Stocks\">Key Risks to Check Before Investing in Control Cable, BPO and Drug Ingredient Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/automotive-control-cables-maker-business-process-services-company-and-pharma-ingredients-maker-stocks-roadmap-vantage-list\/#Final_Thoughts_on_Control_Cable_BPO_and_Drug_Ingredient_Stocks\" title=\"Final Thoughts on Control Cable, BPO and Drug Ingredient Stocks\">Final Thoughts on Control Cable, BPO and Drug Ingredient Stocks<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/automotive-control-cables-maker-business-process-services-company-and-pharma-ingredients-maker-stocks-roadmap-vantage-list\/#What_are_control_cable_BPO_and_drug_ingredient_stocks\" title=\"What are control cable, BPO and drug ingredient stocks?\">What are control cable, BPO and drug ingredient stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/automotive-control-cables-maker-business-process-services-company-and-pharma-ingredients-maker-stocks-roadmap-vantage-list\/#Which_control_cable_BPO_and_drug_ingredient_stocks_are_covered_in_this_list\" title=\"Which control cable, BPO and drug ingredient stocks are covered in this list?\">Which control cable, BPO and drug ingredient stocks are covered in this list?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/automotive-control-cables-maker-business-process-services-company-and-pharma-ingredients-maker-stocks-roadmap-vantage-list\/#Why_do_control_cable_BPO_and_drug_ingredient_stocks_have_a_strong_future_roadmap_in_India\" title=\"Why do control cable, BPO and drug ingredient stocks have a strong future roadmap in India?\">Why do control cable, BPO and drug ingredient stocks have a strong future roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/automotive-control-cables-maker-business-process-services-company-and-pharma-ingredients-maker-stocks-roadmap-vantage-list\/#How_has_Suprajit_Engineering_performed_financially\" title=\"How has Suprajit Engineering performed financially?\">How has Suprajit Engineering performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/automotive-control-cables-maker-business-process-services-company-and-pharma-ingredients-maker-stocks-roadmap-vantage-list\/#How_has_Firstsource_Solutions_performed_financially\" title=\"How has Firstsource Solutions performed financially?\">How has Firstsource Solutions performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/automotive-control-cables-maker-business-process-services-company-and-pharma-ingredients-maker-stocks-roadmap-vantage-list\/#How_has_Divis_Laboratories_performed_financially\" title=\"How has Divi&#8217;s Laboratories performed financially?\">How has Divi&#8217;s Laboratories performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/automotive-control-cables-maker-business-process-services-company-and-pharma-ingredients-maker-stocks-roadmap-vantage-list\/#What_risks_should_investors_check_before_buying_control_cable_BPO_and_drug_ingredient_stocks\" title=\"What risks should investors check before buying control cable, BPO and drug ingredient stocks?\">What risks should investors check before buying control cable, BPO and drug ingredient stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/automotive-control-cables-maker-business-process-services-company-and-pharma-ingredients-maker-stocks-roadmap-vantage-list\/#Is_this_list_of_control_cable_BPO_and_drug_ingredient_stocks_investment_advice\" title=\"Is this list of control cable, BPO and drug ingredient stocks investment advice?\">Is this list of control cable, BPO and drug ingredient stocks investment advice?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Are_Control_Cable_BPO_and_Drug_Ingredient_Stocks\"><\/span><strong>What Are Control Cable, BPO and Drug Ingredient Stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Control cable, BPO and drug ingredient stocks are listed companies that make control cables and driver controls for vehicles, provide customer experience and business process services to global clients, and produce active pharmaceutical ingredients and intermediates. Their earnings depend on vehicle output, client outsourcing budgets and pharma sourcing.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Control_Cable_BPO_and_Drug_Ingredient_Stocks_at_a_Glance\"><\/span><strong>Control Cable, BPO and Drug Ingredient Stocks at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">CMP (Rs)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Market Cap (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Industry P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">ROE (%)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">D\/E<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/suprajit\/suprajit-engineering-ltd-share-price-today\">Suprajit Engineering<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">463.85<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">6,286<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">33.6<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.1<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">12.7<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.69<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/fsl\/firstsource-solutions-ltd-share-price-today\">Firstsource Solutions<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">295.25<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">19,489<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">29.1<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">17.5<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">17.1<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.67<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/divislab\/divi's-laboratories-ltd-share-price-today\">Divi&#8217;s Laboratories<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">11,367<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">241,311<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">82.5<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">15.3<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.00<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>On valuation, Suprajit Engineering trades at a P\/E below the industry P\/E, while Firstsource Solutions and Divi&#8217;s Laboratories trade above it, which reflects the growth the market already expects. Readers comparing control cable, BPO and drug ingredient stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in control cable, BPO and drug ingredient stocks can use the coming numbers to test whether growth is holding.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Do_Control_Cable_BPO_and_Drug_Ingredient_Stocks_Have_a_Strong_Roadmap_in_India\"><\/span><strong>Why Do Control Cable, BPO and Drug Ingredient Stocks Have a Strong Roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Control cable, BPO and drug ingredient stocks have a strong roadmap in India because rising vehicle production, wider outsourcing of customer services and steady global demand for generic drug inputs keep widening the market for these companies.<\/p>\n<ul>\n<li><strong>Control cables.<\/strong> Every vehicle needs precise controls.<\/li>\n<li><strong>Process services.<\/strong> Global firms outsource customer work.<\/li>\n<li><strong>Pharma ingredients.<\/strong> Drug makers need dependable inputs.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Why_Suprajit_Engineering_Features_Among_These_Control_Cable_BPO_and_Drug_Ingredient_Stocks\"><\/span><strong>Why Suprajit Engineering Features Among These Control Cable, BPO and Drug Ingredient Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the control cable, BPO and drug ingredient stocks on this list, Suprajit Engineering is a Bengaluru-based maker of automotive cables and control systems, lighting products and other components for two-wheelers, cars and commercial vehicles, with a presence in many countries.<\/p>\n<p>The company has a return on equity of 12.7%, a debt to equity ratio of 0.69 and a market capitalisation of Rs 6,286 crore. The stock trades at a P\/E of 33.6, below the industry P\/E of 36.1.<\/p>\n<p>Revenue rose from Rs 1,877 crore in FY22 to Rs 3,941 crore in FY26, a compound annual growth rate of 20.4%. Net profit grew from Rs 152 crore in FY23 to Rs 183 crore in FY26, which works out to a compound annual growth rate of 6.3%. In the June 2026 quarter, revenue grew 19.1% year on year to Rs 1,074 crore, while net profit rose 8.6% to Rs 52.2 crore.<\/p>\n<p><strong>Roadmap:<\/strong> The company is widening its mix through lighting, electronics and aftermarket products while keeping its strong cable franchise. A global footprint supports orders from international vehicle makers.<\/p>\n<p><strong>What to watch:<\/strong> Follow growth in new product lines, export programmes and margin trends.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Firstsource_Solutions_Features_Among_These_Control_Cable_BPO_and_Drug_Ingredient_Stocks\"><\/span><strong>Why Firstsource Solutions Features Among These Control Cable, BPO and Drug Ingredient Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the vehicle cable, outsourcing and pharma input shares on this list, Firstsource Solutions, an RPG group company, is a business process management firm serving banks, healthcare payers and providers, and other clients, mainly in the United States and the United Kingdom.<\/p>\n<p>Revenue rose from Rs 5,922 crore in FY22 to Rs 9,564 crore in FY26, a compound annual growth rate of 12.7%. Net profit grew from Rs 537 crore in FY22 to Rs 674 crore in FY26, which works out to a compound annual growth rate of 5.9%.<\/p>\n<p>In the June 2026 quarter, revenue grew 22.8% year on year to Rs 2,731 crore. The company has a return on equity of 17.1%, a debt to equity ratio of 0.67 and a market capitalisation of Rs 19,489 crore. The stock trades at a P\/E of 29.1, above the industry P\/E of 17.5.<\/p>\n<p><strong>Roadmap:<\/strong> It is growing in healthcare and mortgage services, pursuing larger deals and using artificial intelligence to improve productivity. Longer contracts with large clients give it visibility on revenue.<\/p>\n<p><strong>What to watch:<\/strong> Follow contract wins in healthcare and the pace of new technology investments.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Divis_Laboratories_Features_Among_These_Control_Cable_BPO_and_Drug_Ingredient_Stocks\"><\/span><strong>Why Divi&#8217;s Laboratories Features Among These Control Cable, BPO and Drug Ingredient Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the three companies on this list, Divi&#8217;s Laboratories is a Hyderabad-based maker of active pharmaceutical ingredients, intermediates and custom synthesis products, serving large global pharma companies from large-scale manufacturing sites.<\/p>\n<p>In the June 2026 quarter, revenue grew 24.3% year on year to Rs 3,144 crore, while net profit rose 65.5% to Rs 902 crore. Revenue rose from Rs 9,074 crore in FY22 to Rs 11,067 crore in FY26, a compound annual growth rate of 5.1%.<\/p>\n<p>Net profit grew from Rs 1,823 crore in FY23 to Rs 2,568 crore in FY26, which works out to a compound annual growth rate of 12.1%. The company has a return on equity of 15.3%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 241,311 crore. The stock trades at a P\/E of 82.5, above the industry P\/E of 36.0.<\/p>\n<p><strong>Roadmap:<\/strong> The company is a key supplier of ingredients for several widely used generics and has long-standing contract manufacturing relationships with global innovators. Capacity additions at its sites and a growing custom synthesis pipeline support future volumes.<\/p>\n<p><strong>What to watch:<\/strong> Check the order flow in custom synthesis and the commissioning of new capacity.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Suprajit_Engineering_vs_Firstsource_Solutions_vs_Divis_Laboratories_on_Key_Financials\"><\/span><strong>Suprajit Engineering vs Firstsource Solutions vs Divi&#8217;s Laboratories on Key Financials<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table below sets the three control cable, BPO and drug ingredient stocks side by side on revenue, profit and margin, using reported figures.<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY22 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Revenue CAGR (FY22-FY26)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Profit (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Margin<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Suprajit Engineering<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,877<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">3,941<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">20.4%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">183<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">4.6%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Firstsource Solutions<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">5,922<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">9,564<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">12.7%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">674<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">7.1%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Divi&#8217;s Laboratories<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">9,074<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">11,067<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">5.1%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,568<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">23.2%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Firstsource Solutions posts the highest return on equity in this group at 17.1%. Divi&#8217;s Laboratories has the largest FY26 revenue at Rs 11,067 crore, and Suprajit Engineering shows the fastest revenue growth with a 20.4% compound annual rate. A useful habit with control cable, BPO and drug ingredient stocks is to check each new quarterly result against the capacity plans the company described earlier.<\/p>\n<p>The June 2026 quarter, the latest reported, gives a fresh read on momentum:<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Q1 FY26 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Q1 FY27 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Year-on-Year Growth<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Suprajit Engineering<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">902<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,074<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">19.1%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Firstsource Solutions<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,224<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,731<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">22.8%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Divi&#8217;s Laboratories<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,529<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">3,144<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">24.3%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_Check_Before_Investing_in_Control_Cable_BPO_and_Drug_Ingredient_Stocks\"><\/span><strong>Key Risks to Check Before Investing in Control Cable, BPO and Drug Ingredient Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Every theme carries risks that deserve a check before any decision. For these control cable, BPO and drug ingredient stocks, the main points are: Long-term vehicle cable, outsourcing and pharma input shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.<\/p>\n<ul>\n<li><strong>Production cycles.<\/strong> Vehicle output can vary with demand.<\/li>\n<li><strong>Client concentration.<\/strong> A few large clients contribute a big share of revenue.<\/li>\n<li><strong>Regulatory approvals.<\/strong> Plant inspections and approvals can affect supplies.<\/li>\n<\/ul>\n<p>Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/screeners\">Use the Univest Stock Screener<\/a><\/strong> to filter control cable, BPO and drug ingredient stocks by market capitalisation, P\/E, ROE and growth, and build your own shortlist.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Final_Thoughts_on_Control_Cable_BPO_and_Drug_Ingredient_Stocks\"><\/span><strong>Final Thoughts on Control Cable, BPO and Drug Ingredient Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Control cable, BPO and drug ingredient stocks suit investors who prefer to study business strength before price moves. Suprajit Engineering, Firstsource Solutions and Divi&#8217;s Laboratories each have a clear plan to grow. Based on the 11 November 2026 close, Suprajit Engineering trades at Rs 463.85, Firstsource Solutions at Rs 295.25 and Divi&#8217;s Laboratories at Rs 11,367. Valuation matters as much as growth, so compare each company&#8217;s P\/E with its industry P\/E before adding any of these control cable, BPO and drug ingredient stocks to a watchlist.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track control cable, BPO and drug ingredient stocks, set price alerts and get research-backed stock ideas.<\/em><\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h3><span class=\"ez-toc-section\" id=\"What_are_control_cable_BPO_and_drug_ingredient_stocks\"><\/span><strong>What are control cable, BPO and drug ingredient stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Control cable, BPO and drug ingredient stocks are listed companies that make control cables and driver controls for vehicles, provide customer experience and business process services to global clients, and produce active pharmaceutical ingredients and intermediates. Their earnings depend on vehicle output, client outsourcing budgets and pharma sourcing. This list looks at three of them, Suprajit Engineering, Firstsource Solutions and Divi&#8217;s Laboratories, using reported FY22 to FY26 financials and the 11 November 2026 closing prices.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_control_cable_BPO_and_drug_ingredient_stocks_are_covered_in_this_list\"><\/span><strong>Which control cable, BPO and drug ingredient stocks are covered in this list?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This list covers Suprajit Engineering, Firstsource Solutions and Divi&#8217;s Laboratories. Based on the 11 November 2026 close, Suprajit Engineering traded at Rs 463.85, Firstsource Solutions at Rs 295.25 and Divi&#8217;s Laboratories at Rs 11,367. Their return on equity ranges from 12.7% to 17.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 5.1% to 20.4%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_do_control_cable_BPO_and_drug_ingredient_stocks_have_a_strong_future_roadmap_in_India\"><\/span><strong>Why do control cable, BPO and drug ingredient stocks have a strong future roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Control cable, BPO and drug ingredient stocks have a strong roadmap in India because rising vehicle production, wider outsourcing of customer services and steady global demand for generic drug inputs keep widening the market for these companies. The main drivers are as follows. Control cables. Every vehicle needs precise controls. Process services. Global firms outsource customer work. Pharma ingredients. Drug makers need dependable inputs. Together these factors give the companies on this list a visible path for growth over the coming years.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Suprajit_Engineering_performed_financially\"><\/span><strong>How has Suprajit Engineering performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 1,877 crore in FY22 to Rs 3,941 crore in FY26, a compound annual growth rate of 20.4%. Net profit grew from Rs 152 crore in FY23 to Rs 183 crore in FY26, which works out to a compound annual growth rate of 6.3%. In the June 2026 quarter, revenue grew 19.1% year on year to Rs 1,074 crore, while net profit rose 8.6% to Rs 52.2 crore. The company has a return on equity of 12.7%, a debt to equity ratio of 0.69 and a market capitalisation of Rs 6,286 crore. The stock trades at a P\/E of 33.6, below the industry P\/E of 36.1. Looking ahead, the company is widening its mix through lighting, electronics and aftermarket products while keeping its strong cable franchise. A global footprint supports orders from international vehicle makers.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Firstsource_Solutions_performed_financially\"><\/span><strong>How has Firstsource Solutions performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 5,922 crore in FY22 to Rs 9,564 crore in FY26, a compound annual growth rate of 12.7%. Net profit grew from Rs 537 crore in FY22 to Rs 674 crore in FY26, which works out to a compound annual growth rate of 5.9%. In the June 2026 quarter, revenue grew 22.8% year on year to Rs 2,731 crore. The company has a return on equity of 17.1%, a debt to equity ratio of 0.67 and a market capitalisation of Rs 19,489 crore. The stock trades at a P\/E of 29.1, above the industry P\/E of 17.5. Looking ahead, it is growing in healthcare and mortgage services, pursuing larger deals and using artificial intelligence to improve productivity. Longer contracts with large clients give it visibility on revenue.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Divis_Laboratories_performed_financially\"><\/span><strong>How has Divi&#8217;s Laboratories performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 9,074 crore in FY22 to Rs 11,067 crore in FY26, a compound annual growth rate of 5.1%. Net profit grew from Rs 1,823 crore in FY23 to Rs 2,568 crore in FY26, which works out to a compound annual growth rate of 12.1%. In the June 2026 quarter, revenue grew 24.3% year on year to Rs 3,144 crore, while net profit rose 65.5% to Rs 902 crore. The company has a return on equity of 15.3%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 241,311 crore. The stock trades at a P\/E of 82.5, above the industry P\/E of 36.0. Looking ahead, the company is a key supplier of ingredients for several widely used generics and has long-standing contract manufacturing relationships with global innovators. Capacity additions at its sites and a growing custom synthesis pipeline support future volumes.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_risks_should_investors_check_before_buying_control_cable_BPO_and_drug_ingredient_stocks\"><\/span><strong>What risks should investors check before buying control cable, BPO and drug ingredient stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Investors should check a few risks before buying control cable, BPO and drug ingredient stocks. Production cycles. Vehicle output can vary with demand. Client concentration. A few large clients contribute a big share of revenue. Regulatory approvals. Plant inspections and approvals can affect supplies. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_this_list_of_control_cable_BPO_and_drug_ingredient_stocks_investment_advice\"><\/span><strong>Is this list of control cable, BPO and drug ingredient stocks investment advice?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No. This article is educational and uses publicly available data as of the 11 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What are control cable, BPO and drug ingredient stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Control cable, BPO and drug ingredient stocks are listed companies that make control cables and driver controls for vehicles, provide customer experience and business process services to global clients, and produce active pharmaceutical ingredients and intermediates. Their earnings depend on vehicle output, client outsourcing budgets and pharma sourcing. This list looks at three of them, Suprajit Engineering, Firstsource Solutions and Divi's Laboratories, using reported FY22 to FY26 financials and the 11 November 2026 closing prices.\"}},{\"@type\":\"Question\",\"name\":\"Which control cable, BPO and drug ingredient stocks are covered in this list?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This list covers Suprajit Engineering, Firstsource Solutions and Divi's Laboratories. Based on the 11 November 2026 close, Suprajit Engineering traded at Rs 463.85, Firstsource Solutions at Rs 295.25 and Divi's Laboratories at Rs 11,367. Their return on equity ranges from 12.7% to 17.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 5.1% to 20.4%.\"}},{\"@type\":\"Question\",\"name\":\"Why do control cable, BPO and drug ingredient stocks have a strong future roadmap in India?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Control cable, BPO and drug ingredient stocks have a strong roadmap in India because rising vehicle production, wider outsourcing of customer services and steady global demand for generic drug inputs keep widening the market for these companies. The main drivers are as follows. Control cables. Every vehicle needs precise controls. Process services. Global firms outsource customer work. Pharma ingredients. Drug makers need dependable inputs. Together these factors give the companies on this list a visible path for growth over the coming years.\"}},{\"@type\":\"Question\",\"name\":\"How has Suprajit Engineering performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 1,877 crore in FY22 to Rs 3,941 crore in FY26, a compound annual growth rate of 20.4%. Net profit grew from Rs 152 crore in FY23 to Rs 183 crore in FY26, which works out to a compound annual growth rate of 6.3%. In the June 2026 quarter, revenue grew 19.1% year on year to Rs 1,074 crore, while net profit rose 8.6% to Rs 52.2 crore. The company has a return on equity of 12.7%, a debt to equity ratio of 0.69 and a market capitalisation of Rs 6,286 crore. The stock trades at a P\/E of 33.6, below the industry P\/E of 36.1. Looking ahead, the company is widening its mix through lighting, electronics and aftermarket products while keeping its strong cable franchise. A global footprint supports orders from international vehicle makers.\"}},{\"@type\":\"Question\",\"name\":\"How has Firstsource Solutions performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 5,922 crore in FY22 to Rs 9,564 crore in FY26, a compound annual growth rate of 12.7%. Net profit grew from Rs 537 crore in FY22 to Rs 674 crore in FY26, which works out to a compound annual growth rate of 5.9%. In the June 2026 quarter, revenue grew 22.8% year on year to Rs 2,731 crore. The company has a return on equity of 17.1%, a debt to equity ratio of 0.67 and a market capitalisation of Rs 19,489 crore. The stock trades at a P\/E of 29.1, above the industry P\/E of 17.5. Looking ahead, it is growing in healthcare and mortgage services, pursuing larger deals and using artificial intelligence to improve productivity. Longer contracts with large clients give it visibility on revenue.\"}},{\"@type\":\"Question\",\"name\":\"How has Divi's Laboratories performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 9,074 crore in FY22 to Rs 11,067 crore in FY26, a compound annual growth rate of 5.1%. Net profit grew from Rs 1,823 crore in FY23 to Rs 2,568 crore in FY26, which works out to a compound annual growth rate of 12.1%. In the June 2026 quarter, revenue grew 24.3% year on year to Rs 3,144 crore, while net profit rose 65.5% to Rs 902 crore. The company has a return on equity of 15.3%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 241,311 crore. The stock trades at a P\/E of 82.5, above the industry P\/E of 36.0. Looking ahead, the company is a key supplier of ingredients for several widely used generics and has long-standing contract manufacturing relationships with global innovators. Capacity additions at its sites and a growing custom synthesis pipeline support future volumes.\"}},{\"@type\":\"Question\",\"name\":\"What risks should investors check before buying control cable, BPO and drug ingredient stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Investors should check a few risks before buying control cable, BPO and drug ingredient stocks. Production cycles. Vehicle output can vary with demand. Client concentration. A few large clients contribute a big share of revenue. Regulatory approvals. Plant inspections and approvals can affect supplies. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.\"}},{\"@type\":\"Question\",\"name\":\"Is this list of control cable, BPO and drug ingredient stocks investment advice?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No. This article is educational and uses publicly available data as of the 11 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Control Cable, BPO and Drug Ingredient Stocks with a strong future roadmap: Suprajit Engineering, Firstsource Solutions and Divi&#8217;s Laboratories. Compare price, valuation, return on equity and revenue growth as of 11 November 2026.<\/p>\n","protected":false},"author":29,"featured_media":344485,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[845],"tags":[3803,22478,22477,457,7676,22479,22481,22480,9926,15396],"class_list":["post-344486","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-best-stocks","tag-best-stocks","tag-bpo-and-drug-ingredient-stocks","tag-control-cable","tag-divis-laboratories","tag-firstsource-solutions","tag-outsourcing-and-pharma-input-shares","tag-process-outsourcing-and-api-stocks","tag-push-pull-cable","tag-suprajit-engineering","tag-vehicle-cable"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["344485"],"rank_math_title":["Control Cable, BPO and Drug Ingredient Stocks"],"rank_math_description":["Compare 3 control cable, BPO and drug ingredient stocks with a strong future roadmap on CMP, market cap, P\/E, ROE and revenue growth. Data as of 11 Nov 2026."],"rank_math_focus_keyword":["control cable, BPO and drug ingredient stocks"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/11\/3-automotive-control-cables-maker-business-process-services-company-and-pharma.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/344486","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/29"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=344486"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/344486\/revisions"}],"predecessor-version":[{"id":344487,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/344486\/revisions\/344487"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/344485"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=344486"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=344486"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=344486"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}